Drug
LU Af28996
LU Af28996: highest development phase Phase 2, developed by Lundbeck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AF28996 NCT07514858 | Phase 2 | Parkinson's Disease |
| Lu AF28996 NCT06004180 | Phase 1 | Parkinson Disease |
| Lu AF28996 NCT07513441 | Phase 1 | Parkinson Disease |
Latest
Follow LU Af28996 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.